Fortis Healthcare Ltd.
FORTISHealthcare filings
We hold this company’s filings and have not read the financial statements out of them yet. Every filing on record is listed under filings, and each one opens.
Earnings calls
18 transcript(s)/analyst meet(s) served; 0 document(s) on file are not transcripts (cover letters, duplicates, unresolved) and are excluded. Speaker attribution is shown only where the segmenter attributes ≥ 95% of sentences to management or analysts (0 of 18 documents here); elsewhere sentences render unattributed.
| Kind | Date | Period | Served | Attribution rate |
|---|---|---|---|---|
| TRANSCRIPT | 20220531 | 2022-03-31 | yes | |
| TRANSCRIPT | 20220811 | 2022-06-30 | yes | |
| TRANSCRIPT | 20221118 | 2022-09-30 | yes | |
| TRANSCRIPT | 20230216 | 2022-12-31 | yes | |
| TRANSCRIPT | 20230526 | 2023-03-31 | yes | |
| TRANSCRIPT | 20230811 | 2023-06-30 | yes | |
| TRANSCRIPT | 20231115 | 2023-09-30 | yes | |
| TRANSCRIPT | 20240210 | 2023-12-31 | yes | |
| TRANSCRIPT | 20240528 | 2024-03-31 | yes | |
| TRANSCRIPT | 20240812 | 2024-06-30 | yes | |
| TRANSCRIPT | 20241113 | 2024-09-30 | yes | |
| TRANSCRIPT | 20250214 | 2024-12-31 | yes | |
| TRANSCRIPT | 20250526 | 2025-03-31 | yes | |
| TRANSCRIPT | 20250811 | 2025-06-30 | yes | |
| TRANSCRIPT | 20251117 | 2025-09-30 | yes | |
| TRANSCRIPT | 20260220 | 2025-12-31 | yes | |
| TRANSCRIPT | 20260529 | 2026-03-31 | yes | |
| TRANSCRIPT | 20260811 | 2026-06-30 | yes |
FORTIS
files the standard Schedule III statements. Every figure below opens to the filing it was read from; where a figure is not shown, the reason is printed in its place.
Identity
| Statement division | general |
| Scope served | consolidated |
| Panels on this page | 4 |
Market
No split, bonus or consolidation is on record for this company inside the period this price series covers, so the closes need no adjustment.
| Last close | 877.35 |
| 52-week range | 788.75 – 1095.25 |
| Return 1M | -5.04% |
| Return 3M | -8.11% |
| Return 1Y | -8.65% |
| Return 3Y | 164.1% |
| Return 5Y | 223.09% |
| Market capitalisation | not shown — we could not confirm it |
| Shares outstanding | not shown — we could not confirm it |
| P/E | not shown — we could not confirm it |
| P/B | not shown — we could not confirm it |
| EV/EBITDA | not shown — we could not confirm it |
Latest quarter filed — period ending 2026-06-30
In INR crore except per-share figures. `period_id` is the period the filing names for the number; the date beside each cell is when it was filed.
| Revenue from operations | 2,545.00 |
| Other income | 14.00 |
| Total income | 2,560.00 |
| Cost of materials consumed | 0.00 |
| Purchases of stock-in-trade | 586.00 |
| Changes in inventories | -13.00 |
| Employee benefit expense | 404.00 |
| Finance costs | 80.00 |
Ownership — 2026-06-30, and the change from 2026-03-31
| Holder | Per cent | Change |
|---|---|---|
| promoter and promoter group | 0.31 | 0.00 |
| institutions foreign | 0.25 | -0.01 |
| institutions domestic | 0.32 | 0.01 |
| mutual funds | 0.26 | 0.00 |
| public | 0.69 | 0.00 |
Documents on file
| Class | Most recent | On file |
|---|---|---|
| TRANSCRIPT | 2026-06-30 | 18 |
Financial statements
Filed results, consolidated, in INR crore except per-share figures. Every figure opens to the filing it was read from. Quarterly and annual columns are the periods the filing itself names, never a document date.
Quarterly results, as filed
| Line | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 1,607.00 | 1,560.00 | 1,643.00 | 1,657.00 | 1,770.00 | 1,680.00 | 1,786.00 | 1,859.00 | 1,988.00 | 1,928.00 | 2,007.00 | 2,167.00 | 2,331.00 | 2,265.00 | 2,365.00 | 2,545.00 |
| Other income | 16.00 | 12.00 | 14.00 | 8.00 | 14.00 | 7.00 | 10.00 | 13.00 | 13.00 | 21.00 | 20.00 | 15.00 | 23.00 | 8.00 | 4.00 | 14.00 |
| Total income | 1,623.00 | 1,572.00 | 1,656.00 | 1,666.00 | 1,783.00 | 1,686.00 | 1,796.00 | 1,872.00 | 2,002.00 | 1,949.00 | 2,027.00 | 2,182.00 | 2,354.00 | 2,273.00 | 2,369.00 | 2,560.00 |
| Cost of materials consumed | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of stock-in-trade | 365.00 | 365.00 | 378.00 | 396.00 | 416.00 | 389.00 | 403.00 | 455.00 | 466.00 | 457.00 | 460.00 | 518.00 | 548.00 | 522.00 | 521.00 | 586.00 |
| Changes in inventories | -0.00 | -7.00 | 5.00 | 3.00 | -3.00 | 5.00 | 11.00 | -2.00 | -5.00 | -4.00 | 3.00 | -4.00 | -8.00 | -6.00 | -2.00 | -13.00 |
| Employee benefit expense | 268.00 | 263.00 | 261.00 | 285.00 | 281.00 | 282.00 | 272.00 | 295.00 | 290.00 | 294.00 | 287.00 | 313.00 | 317.00 | 328.00 | 340.00 | 404.00 |
| Finance costs | 33.00 | 33.00 | 32.00 | 31.00 | 32.00 | 33.00 | 35.00 | 35.00 | 36.00 | 45.00 | 68.00 | 70.00 | 75.00 | 86.00 | 84.00 | 80.00 |
| Depreciation and amortisation | 77.00 | 83.00 | 82.00 | 79.00 | 84.00 | 87.00 | 92.00 | 91.00 | 95.00 | 97.00 | 102.00 | 101.00 | 106.00 | 120.00 | 122.00 | 122.00 |
| Other expenses | 671.00 | 663.00 | 729.00 | 702.00 | 746.00 | 720.00 | 720.00 | 768.00 | 802.00 | 805.00 | 821.00 | 849.00 | 919.00 | 916.00 | 974.00 | 1,031.00 |
| Total expenses | 1,414.00 | 1,400.00 | 1,485.00 | 1,496.00 | 1,556.00 | 1,516.00 | 1,532.00 | 1,643.00 | 1,685.00 | 1,696.00 | 1,742.00 | 1,847.00 | 1,956.00 | 1,965.00 | 2,039.00 | 2,210.00 |
| Profit before exceptional items and tax | 209.00 | 172.00 | 171.00 | 170.00 | 228.00 | 171.00 | 264.00 | 229.00 | 317.00 | 254.00 | 285.00 | 335.00 | 398.00 | 308.00 | 330.00 | 349.00 |
| Exceptional items | 52.00 | 11.00 | 11.00 | 1.00 | 4.00 | 8.00 | 3.00 | 0.00 | -60.00 | 24.00 | -54.00 | 13.00 | 24.00 | -46.00 | -12.00 | 10.00 |
| Profit before tax | 260.00 | 183.00 | 182.00 | 171.00 | 231.00 | 179.00 | 267.00 | 229.00 | 257.00 | 277.00 | 232.00 | 348.00 | 422.00 | 262.00 | 318.00 | 359.00 |
| Current tax | 33.00 | 33.00 | 34.00 | 47.00 | 49.00 | 39.00 | 76.00 | 52.00 | 52.00 | 45.00 | 34.00 | 40.00 | 48.00 | 55.00 | 66.00 | 86.00 |
| Deferred tax | 17.00 | 11.00 | 11.00 | 0.00 | 0.00 | 10.00 | -8.00 | 4.00 | 16.00 | -20.00 | 14.00 | 44.00 | 49.00 | 13.00 | -13.00 | 4.00 |
| Tax expense | 50.00 | 44.00 | 45.00 | 47.00 | 49.00 | 49.00 | 68.00 | 56.00 | 68.00 | 25.00 | 49.00 | 84.00 | 97.00 | 68.00 | 53.00 | 90.00 |
| Profit for the period | 218.00 | 142.00 | 138.00 | 124.00 | 184.00 | 134.00 | 203.00 | 174.00 | 193.00 | 254.00 | 188.00 | 267.00 | 329.00 | 197.00 | 271.00 | 273.00 |
| Profit attributable to owners | 204.00 | 130.00 | 133.00 | 112.00 | 174.00 | 135.00 | 179.00 | 166.00 | 176.00 | 248.00 | 184.00 | 260.00 | 322.00 | 194.00 | 266.00 | 266.00 |
| Profit attributable to non-controlling interests | 14.00 | 13.00 | 6.00 | 12.00 | 10.00 | -0.00 | 24.00 | 8.00 | 17.00 | 6.00 | 4.00 | 6.00 | 7.00 | 4.00 | 5.00 | 6.00 |
| Other comprehensive income | -15.00 | 3.00 | 28.00 | 2.00 | -1.00 | 0.00 | 0.00 | -0.00 | -1.00 | 0.00 | -3.00 | -0.00 | 6.00 | 4.00 | 2.00 | 0.00 |
| Total comprehensive income | 203.00 | 145.00 | 166.00 | 126.00 | 183.00 | 134.00 | 203.00 | 174.00 | 192.00 | 255.00 | 185.00 | 266.00 | 335.00 | 202.00 | 274.00 | 273.00 |
| Earnings per share, basic | 2.71 | 1.72 | 1.76 | 1.48 | 2.30 | 1.78 | 2.37 | 2.20 | 2.34 | 3.28 | 2.44 | 3.45 | 4.26 | 2.57 | 3.52 | 3.53 |
| Earnings per share, diluted | 2.71 | 1.72 | 1.76 | 1.48 | 2.30 | 1.78 | 2.37 | 2.20 | 2.34 | 3.28 | 2.44 | 3.45 | 4.26 | 2.57 | 3.52 | 3.53 |
Annual results, as filed
| Line | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 4,469.00 | 4,632.00 | 4,030.00 | 5,718.00 | 6,298.00 | 6,893.00 | 7,783.00 | 9,128.00 |
| Other income | 92.00 | 53.00 | 47.00 | 27.00 | 62.00 | 38.00 | 67.00 | 51.00 |
| Total income | 4,562.00 | 4,685.00 | 4,077.00 | 5,745.00 | 6,359.00 | 6,931.00 | 7,850.00 | 9,178.00 |
| Cost of materials consumed | 928.00 | 964.00 | 976.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of stock-in-trade | 0.00 | 0.00 | 0.00 | 1,403.00 | 1,455.00 | 1,603.00 | 1,838.00 | 2,109.00 |
| Changes in inventories | 0.00 | 0.00 | 0.00 | -46.00 | 0.00 | 15.00 | -8.00 | -20.00 |
| Employee benefit expense | 914.00 | 916.00 | 849.00 | 973.00 | 1,047.00 | 1,120.00 | 1,167.00 | 1,297.00 |
| Finance costs | 337.00 | 205.00 | 166.00 | 147.00 | 129.00 | 131.00 | 184.00 | 314.00 |
| Depreciation and amortisation | 233.00 | 292.00 | 291.00 | 301.00 | 316.00 | 342.00 | 386.00 | 449.00 |
| Other expenses | 2,402.00 | 2,143.00 | 1,801.00 | 2,318.00 | 2,695.00 | 2,887.00 | 3,197.00 | 3,658.00 |
| Total expenses | 4,814.00 | 4,520.00 | 4,082.00 | 5,096.00 | 5,641.00 | 6,099.00 | 6,765.00 | 7,807.00 |
| Profit before exceptional items and tax | -252.00 | 165.00 | -5.00 | 649.00 | 718.00 | 832.00 | 1,085.00 | 1,372.00 |
| Exceptional items | -222.00 | 62.00 | 1.00 | 315.00 | 74.00 | 16.00 | -89.00 | -22.00 |
| Profit before tax | -475.00 | 227.00 | -4.00 | 964.00 | 792.00 | 848.00 | 996.00 | 1,350.00 |
| Current tax | 152.00 | 229.00 | 100.00 | 172.00 | 130.00 | 190.00 | 182.00 | 208.00 |
| Deferred tax | -38.00 | -81.00 | -1.00 | 26.00 | 51.00 | 23.00 | 15.00 | 93.00 |
| Tax expense | 114.00 | 148.00 | 99.00 | 198.00 | 181.00 | 213.00 | 198.00 | 302.00 |
| Profit for the period | -224.00 | 91.00 | -56.00 | 790.00 | 633.00 | 645.00 | 809.00 | 1,064.00 |
| Profit attributable to owners | — | 136.00 | -110.00 | 555.00 | 589.00 | 599.00 | 774.00 | 1,042.00 |
| Profit attributable to non-controlling interests | — | 16.00 | 54.00 | 235.00 | 44.00 | 46.00 | 35.00 | 22.00 |
| Other comprehensive income | -45.00 | 0.00 | 10.00 | -46.00 | -8.00 | 2.00 | -4.00 | 13.00 |
| Total comprehensive income | -269.00 | 92.00 | -46.00 | 743.00 | 625.00 | 647.00 | 806.00 | 1,077.00 |
| Earnings per share, basic | -3.70 | 0.77 | -1.45 | 7.35 | 7.80 | 7.93 | 10.26 | 13.80 |
| Earnings per share, diluted | -3.70 | 0.77 | -1.45 | 7.35 | 7.80 | 7.93 | 10.26 | 13.80 |
Balance sheet, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 12,278.00 | 12,434.00 | 12,785.00 | 13,289.00 | 13,597.00 | 13,692.00 | 15,013.00 | 15,966.00 |
| Non-current assets | 10,451.00 | 10,345.00 | 10,856.00 | 11,097.00 | 11,221.00 | 11,527.00 | 12,477.00 | 14,147.00 |
| Current assets | 1,826.00 | 1,832.00 | 1,929.00 | 2,192.00 | 2,375.00 | 2,164.00 | 2,536.00 | 1,819.00 |
| Property, plant and equipment | 4,968.00 | 4,850.00 | 5,039.00 | 5,268.00 | 5,578.00 | 5,848.00 | 6,599.00 | 5,348.00 |
| Capital work-in-progress | 237.00 | 228.00 | 525.00 | 540.00 | 435.00 | 404.00 | 306.00 | 432.00 |
| Goodwill | 4,133.00 | 4,141.00 | 4,176.00 | 4,194.00 | 4,194.00 | 4,194.00 | 4,526.00 | 4,721.00 |
| Other intangible assets | 454.00 | 436.00 | 421.00 | 412.00 | 399.00 | 381.00 | 576.00 | 621.00 |
| Inventories | 120.00 | 123.00 | 123.00 | 107.00 | 115.00 | 115.00 | 127.00 | 135.00 |
| Trade receivables | 627.00 | 582.00 | 693.00 | 628.00 | 793.00 | 784.00 | 1,017.00 | 1,044.00 |
| Cash and cash equivalents | 127.00 | 141.00 | 90.00 | 235.00 | 266.00 | 140.00 | 101.00 | 407.00 |
| Total equity and liabilities | 12,278.00 | 12,434.00 | 12,785.00 | 13,289.00 | 13,597.00 | 13,692.00 | 15,013.00 | 15,966.00 |
| Equity | 7,788.00 | 8,100.00 | 8,480.00 | 8,556.00 | 8,730.00 | 9,169.00 | 9,693.00 | 10,169.00 |
| Equity share capital | 755.00 | 755.00 | 755.00 | 755.00 | 755.00 | 755.00 | 755.00 | 755.00 |
| Other equity | 6,193.00 | 6,487.00 | 6,855.00 | 6,908.00 | 7,092.00 | 8,162.00 | 8,938.00 | 9,141.00 |
| Total liabilities | 4,490.00 | 4,333.00 | 4,305.00 | 4,733.00 | 4,867.00 | 4,522.00 | 5,320.00 | 5,798.00 |
| Non-current liabilities | 3,168.00 | 2,907.00 | 1,391.00 | 1,562.00 | 1,484.00 | 2,915.00 | 3,597.00 | 3,676.00 |
| Current liabilities | 1,321.00 | 1,314.00 | 2,914.00 | 3,170.00 | 3,380.00 | 1,607.00 | 1,722.00 | 2,121.00 |
| Borrowings, non-current | 1,019.00 | 755.00 | 823.00 | 741.00 | 888.00 | 2,311.00 | 2,929.00 | 2,401.00 |
| Borrowings, current | 212.00 | 171.00 | 210.00 | 117.00 | 298.00 | 164.00 | 266.00 | 471.00 |
| Trade payables | 710.00 | 714.00 | 807.00 | 728.00 | 842.00 | 808.00 | 956.00 | 943.00 |
Cash flow, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Net cash from operating activities | 281.00 | 822.00 | 475.00 | 1,100.00 | 531.00 | 1,424.00 | 676.00 | 1,602.00 |
| Net cash from investing activities | -170.00 | -374.00 | -386.00 | -886.00 | -308.00 | -779.00 | -986.00 | -1,538.00 |
| Net cash from financing activities | -160.00 | -471.00 | -146.00 | -86.00 | -315.00 | -714.00 | 246.00 | 164.00 |
| Purchase of property, plant and equipment | 221.00 | 447.00 | 499.00 | 942.00 | 355.00 | 847.00 | 1,066.00 | 946.00 |
| Net increase in cash | -51.00 | -21.00 | -57.00 | 125.00 | -92.00 | -70.00 | -64.00 | 228.00 |
| con:CFO.BEFORE_TAX | 506.00 | 1,096.00 | 518.00 | 1,326.00 | 654.00 | 1,534.00 | 810.00 | 1,871.00 |
| con:INTEREST_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 30.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INTEREST_PAID.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:DIVIDENDS_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:TAX_PAID.OPERATING | 164.00 | 274.00 | 42.00 | 222.00 | 123.00 | 110.00 | 134.00 | 270.00 |
| con:CF_OTHER.OPERATING | -61.00 | 0.00 | 0.00 | -34.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_PURCHASED | 0.00 | 0.00 | 0.00 | 48.00 | 48.00 | 0.00 | 175.00 | 0.00 |
| con:INVESTMENTS_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 48.00 | 0.00 | 170.00 | 0.00 |
| con:PPE_DISPOSALS | 13.00 | 22.00 | 6.00 | 14.00 | 8.00 | 40.00 | 0.00 | 17.00 |
| con:CF_INVESTING.SUBSIDIARIES_SOLD | 0.00 | 0.00 | 150.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.SUBSIDIARIES_ACQUIRED | 0.00 | 12.00 | 34.00 | 0.00 | 0.00 | 28.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Who owns it
The shareholding pattern filed with the exchange every quarter, as a series. Percentages are of total shares. Each figure names the filing it was read from and the date it was filed.
| Holder | 2022-12-31 | 2023-03-31 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter and promoter group | 31.17 | 31.17 | 31.17 | 31.17 | 31.17 | 31.17 | 31.17 | 31.17 | 31.17 | 31.17 | 0.31 | 0.31 | 0.31 | 0.31 |
| Domestic institutions | 20.38 | 20.70 | 22.16 | 29.41 | 31.15 | 32.31 | 30.73 | 30.05 | 29.46 | 29.79 | 0.29 | 0.29 | 0.31 | 0.32 |
| Mutual funds | — | — | — | — | — | — | — | — | — | 26.07 | 0.25 | 0.24 | 0.26 | 0.26 |
| Insurance companies | 1.64 | 2.07 | 2.39 | 3.12 | 3.32 | 3.37 | 2.20 | 2.08 | 2.37 | 2.38 | 0.03 | 0.03 | 0.04 | 0.05 |
| Foreign institutions | 31.01 | 31.22 | 30.03 | 23.71 | 23.24 | 23.31 | 25.26 | 26.77 | 27.40 | 27.17 | 0.28 | 0.28 | 0.26 | 0.25 |
| Government | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Public | 68.83 | 68.83 | 68.83 | 68.83 | 68.83 | 68.83 | 68.83 | 68.83 | 68.83 | 68.83 | 0.69 | 0.69 | 0.69 | 0.69 |
| Non-institutional | 17.44 | 16.92 | 16.64 | 15.71 | 14.45 | 13.21 | 12.84 | 12.01 | 11.97 | 11.87 | 0.12 | 0.12 | 0.12 | 0.11 |
| Shares outstanding | 754958148 | 754958148 | 754958148 | 754958148 | 754958148 | 754958148 | 754958148 | 754958148 | 754958148 | 754958148 | 754958148 | 754958148 | 754958148 | 754958148 |
Related parties
Transactions with related parties as disclosed to the exchange for the period ending 2024-09-30, by counterparty, largest first. Amounts are as filed. Each row names the filing and the date it was filed.
| Counterparty | Relationship | Type | Amount in the period | Transactions |
|---|---|---|---|---|
| Lanka Hospitals Corporation Plc | Associate Company | Any other transaction | 600,685,000.00 | 3 |
| Acibadem Teknoloj A.S | Enterprises owned or significantly | Any other transaction | 67,085,000.00 | 5 |
| Dr. Ashutosh Raghuvanshi | Managing Director and Chief Execut | Any other transaction, Remuneration | 66,605,000.00 | 2 |
| Mr. Vivek Kumar Goyal | Chief Financial Officer | Remuneration | 41,062,000.00 | 1 |
| Gleneagles Healthcare India Pvt Limited | Enterprises owned or significantly | Sale of goods or services | 22,288,000.00 | 1 |
| NYLIM Jacob Ballas India Fund III LLC | Enterprises having significant inl | Dividend paid | 21,020,000.00 | 1 |
| Agilus Diagnostics Nepal Private Limited | Joint venture company | Any other transaction, Sale of goods or services | 19,631,000.00 | 2 |
| Fortis C-Doc Healthcare Limited | Joint venture company | Any other transaction, Sale of goods or services | 14,733,000.00 | 15 |
| Resurgence PE Investments Limited | Enterprises having significant inl | Dividend paid | 10,664,000.00 | 1 |
| Mr. Ravi Rajagopal | Independent Director | Any other transaction | 7,576,000.00 | 5 |
| Ms. Shailaja Chandra | Independent Director | Any other transaction | 6,400,000.00 | 4 |
| Mr. Indrajit Banerjee | Independent Director | Any other transaction | 6,006,000.00 | 3 |
| Ms. Suvalaxmi Chakrabarty | Independent Director | Any other transaction | 6,005,000.00 | 4 |
| Mr. satyendra chauhan | Company Secretary | Remuneration | 5,098,000.00 | 1 |
| RHT Health Trust | Associate Company | Any other transaction, Sale of goods or services | 2,308,000.00 | 2 |
What management said
Every earnings call we hold for this company, read in full. Prepared remarks are separated from the question-and-answer session and every paragraph names who said it and on which page. These are management’s own words, not filed figures.
| Date | Quarter | Who spoke | |
|---|---|---|---|
| 2026-08-11 | Q1FY27 | Read the call | |
| 2026-05-29 | Q4FY26 | Read the call | |
| 2026-02-20 | Q3FY26 | Read the call | |
| 2025-11-17 | Q2FY26 | Read the call | |
| 2025-08-11 | Q1FY26 | AGILUS DIAGNOSTICS LIMITED, DIAGNOSTICS LIMITED, LIMITED | Read the call |
| 2025-05-26 | Q4FY25 | AGILUS DIAGNOSTICS LIMITED, LIMITED | Read the call |
| 2025-02-14 | Q3FY25 | AGILUS DIAGNOSTICS LIMITED, LIMITED | Read the call |
| 2024-11-13 | Q2FY25 | AGILUS DIAGNOSTICS, LIMITED, OFFICER – AGILUS DIAGNOSTICS | Read the call |
| 2024-08-12 | Q1FY25 | Read the call | |
| 2024-05-28 | Q4FY24 | Read the call | |
| 2024-02-10 | Q3FY24 | FORTIS HEALTHCARE LIMITED, LIMITED | Read the call |
| 2023-11-15 | Q2FY24 | LIMITED | Read the call |
| 2023-08-11 | Q1FY24 | LIMITED | Read the call |
| 2023-05-26 | Q4FY23 | OFFICER, SRL. | Read the call |
| 2023-02-16 | Q3FY23 | Read the call | |
| 2022-11-18 | Q2FY23 | LIMITED | Read the call |
| 2022-08-11 | Q1FY23 | Read the call | |
| 2022-05-31 | Q4FY22 | FORTIS HEALTHCARE LIMITED, LIMITED | Read the call |
What they said about it, quarter by quarter
| Topic | Q3FY24 | Q3FY25 | Q3FY26 | Q4FY22 | Q4FY23 | Q4FY24 | Q4FY25 | Q4FY26 |
|---|---|---|---|---|---|---|---|---|
| Capex | Any capex number you can share in, let's say, last 12 months, 18 months, which has boosted your capabilities on these onco and neuro cases, any capex … | So, capex for all the brownfield projects that we are moving forward and there is a capex requirement for normal maintenance also. | But at the same time, we are also going to expand and start the expansion work for creating further beds so that the capacity can be taken to 300 beds… | Can you just share the capex number that we should factor in for FY2023 and 2024? | Just to put some numbers in context for this, out of total CAPEX spent of about INR 300 crores in Financial Year '23 approximately INR 200 crore has b… | Doctor my question was regarding our CAPEX plan, which we have planned for next few years on the Brownfield side. | — | To highlight our capital expenditure in financial year '26 stood at approximately INR700 crores, reflecting our confidence to further scale up operati… |
| Capital allocation | To that effect, we have divested two of our loss-making facilities in Chennai, first the Arcot, Vadapalani facility in July 23, followed by the Malar … | And is this a possibility that we could look at divestments, some of these other 3 as well? | The increase in debt was primarily due to the fund raised or to part finance the acquisition of PE stake in Agilus Diagnostics by the company, acquisi… | SRL has seen a significant turnaround aided both by the higher volumes of COVID tests in Q1 and Q4 of FY2022 and its acquisition of DDRC, SRL joint ve… | Before I delve into Quarter 4 and the full financial year results I am pleased to inform you that our Board has recommended a maiden dividend of INR 1… | Before discussing our Q4 and full Financial Year Results, I am delighted to announce that our Board has recommended a dividend of Rs. | So this year, of course, there is a one-off of relating to the brand transition and some one-offs relating to the legal fees and some contingent consi… | To begin with, I'm pleased to inform you that our Board has recommended a dividend of INR1 per share, which is equivalent to 10% of the face value for… |
| Costs | Any quantum you want to share Vivek what those cost savings are? | — | — | Sir one question I was thinking what kind of cost pressures in general you are seeing for both your hospital and diagnostic business and are you in a … | One last question pre-COVID and post-COVID in terms of the cost, inflation cost, manpower cost, doctor cost or any other talent cost, have you seen an… | While these are ongoing exercise, cost saving and optimization across select expense lines have also had a positive impact on our P&L in the year. | — | — |
| Debt and cash | Our net debt at the end of Q3 financial '24 stands at INR 518 crores against INR 471 crores at the end of Q3 of financial year. | So after acquiring private equity stake, our gross debt is around INR 2,300 crores at consol level and net debt of around INR 2,000 crores. | — | We have reduced our debt by approximately INR 300 Crores and have a net debt of INR 549 Crores as of March 31, 2022. | Our net debt stands at INR 330 crores as of 31st of March 2023 compared to INR 549 crore as on 31st March, 2022. | Even if you have to pay that money to the PE and buy out their portion, still it would be only a cash flow in, right? | And as a result of that, based on the future profitability and cash flow, we have to adjust the carrying value of the assets. | — |
| Demand | What is the pipeline looking from a divestment perspective? | We do have some things in the pipeline, which we are evaluating, and we would come back at the right time to inform you about them. | There are some beds in pipeline for Noida and that will further add 50 beds, maybe probably, in this current financial year. | We have taken a slew of measures to improve our customer experience from live phlebotomist tracking to introducing smart health reports and being avai… | The transition to next generation diagnostics, digitization of diagnostics, along the value chain and the customer demand for omni- channel and on-dem… | And sir, how we did last year on international patient demand. | And land costs being what they are in -- especially in Greater Mumbai area, which is of great interest to us and we believe has a lot of potential and… | We believe that mental health will increasingly demand more care and dedicated infrastructure distinct from the multi-specialty hospital space and hen… |
| Guidance | As you rightly mentioned about margins, we are moving towards our target and the guidance given earlier of 20% margin by the year-end. | Any guidance on when the facility can breakeven? | We continue to make strong progress across our strategic growth levers, which we expect will drive sustainable growth and further strengthen our posit… | The first one is on the hospital business, so you said in March we have reached 60% plus occupancy if I recollect the number right, so just the outloo… | So, just want to understand what should we expect in the next 18 to 24 months in this business? | In parallel, we also acquired a potential 450 bedded facility in Manesar, Gurugram that we expect to commission shortly, which would further strengthe… | So, on margin expansion, we are sticking to our guidance earlier where we said that we want to achieve a margin expansion nearer to the some of the be… | Of these in financial year '27, we expect to add capacity of more than 400 beds with a new tower at FMRI expected to be operationalized within weeks a… |
| Margin | February 08, 2024 To highlight the contribution of hospital operating EBITDA increased to 88% in Q3 of financial year '24 versus 76% in Q3 of financia… | So is it fair to assume that there isn't too much cost benefit or margin savings that we will see from the asset being divested like we saw the last 2… | Both our hospitals and diagnostic businesses witnessed a sustained growth momentum and delivered margin expansion compared to the corresponding quarte… | Our balance sheet remains healthy with a net debt to EBITDA of 0.6x versus 1.04x over the corresponding previous year. | A consolidated EBITDA stood at INR 1,163 crores compared to INR 1,096 crores in Financial Year '22. | Our consolidated operating EBITDA increased 15.1% to Rs. | On the hospital business, now that we have started seeing a fair bit of traction on the margin, how should we look at the margin expansion from 20.5%,… | Our consolidated operating EBITDA increased 31.3% to INR2,085 crores, which translates into a margin of 22.8% in financial year '26 versus 20.4% in fi… |
| People | — | If you could kind of give us a little bit of how the industry landscape is looking like, especially on hiring and retaining talent? | And in terms of doctors, et cetera, hiring doctors because Bangalore is another market, which we are seeing a fair bit of capacity coming on board, so… | — | — | We will continue to deepen our network, drive further utilization of existing infrastructure, reinforce our test menu and focus on technology to enhan… | We also had some attrition of clinician here. | And my second question is, given that we are seeing new capacity come in, both in Gurgaon and in Noida also you've seen, any comment that you can make… |
| Pricing | February 08, 2024 If you see our price increase at overall level from the previous year, it is coming around 1%, 1.5% only. | Or is there some pricing element that is also there on a Y-o-Y basis that is helping us keep the ARPOB buoyancy where it is? | So have you started seeing impact of better pricing in ECHS, CGHS, etc.? | May 26, 2022 able to absorb some of this cost through price increase and the mixed increase in the ARPOB as I mentioned going towards higher payers, b… | Firstly, on SRL, some of your peers have taken price increases on some of the tests in their portfolio. | Just the first one, given the Supreme Court order or whatever the NGO petition around standardized pricing. | — | But considering the price increase happening in that part of the portfolio, how do you see this business moving in, say, '27-'28 in terms of growth? |
| Revenue growth | For the 9 months of financial year, our consolidated revenue stood at INR 5,107 crores, a growth of 9.7% over the corresponding previous period. | And I'm first talking of the Hospital business, and our revenue growth should be somewhere around 14% year-on- year. | For the quarter, our consolidated revenues were at INR2,265 crores, registering a growth of 17.5% over the corresponding previous period. | We recorded a consolidated topline of INR 1378 Crores, a growth of 10% over Q4 of FY2021. Our EBITDA margins were better at 16.5% versus 16.3% and our… | Yearly Performance Update For the Financial Year 2023 consolidated revenues for the Company stood at INR 6,298 crores compared to INR 5,718 crores in … | 6,893 crores, a growth of 9.5% over Financial Year ‘23. | So you believe based on the Agilus momentum currently, we're confident of double-digit revenue growth. | For the financial year 2026, consolidated revenues for the company stood at INR9,128 crores, a growth of 17.3% over the financial year '25. |